更新于：2024-07-01
Clascoterone
克拉司酮
更新于：2024-07-01
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-08-26), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C24H34O5 |
InChIKeyGPNHMOZDMYNCPO-PDUMRIMRSA-N |
CAS号19608-29-8 |
关联
27
项与 克拉司酮 相关的临床试验Histologic and LCMS Evaluation of the Sebaceous Gland Changes Induced by Clascoterone Cream 1%
An Open Phase I Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Single Dose and Repeat Dose Topical Administrations of Clascoterone Cream, 1% in Healthy Chinese Adult Subjects
1%柯拉特龙乳膏治疗面部寻常痤疮的有效性和安全性的多中心、随机、双盲、安慰剂对照临床研究
100 项与 克拉司酮 相关的临床结果
登录后查看更多信息
100 项与 克拉司酮 相关的转化医学
登录后查看更多信息
100 项与 克拉司酮 相关的专利（医药）
登录后查看更多信息
703
项与 克拉司酮 相关的文献（医药）2024-12-31The Journal of dermatological treatment
The primary role of sebum in the pathophysiology of acne vulgaris and its therapeutic relevance in acne management
Review
作者: Del Rosso, James Q ; Kircik, Leon
BACKGROUND:
Sebum physiology and its contributions to acne vulgaris (AV) pathophysiology have been long debated. Within the pilosebaceous unit, androgens drive sebocyte production of sebum, comprising mono-, di-, and triglycerides (the latter converted to fatty acids); squalene; cholesterol; cholesterol esters; and wax esters. Upon release to the skin surface, human sebum has important roles in epidermal water retention, antimicrobial defenses, and innate immune responses.
AIMS:
Alterations in sebum alone and with other pathogenic factors (inflammation, follicular hyperkeratinization, and Cutibacterium acnes [C. acnes] proliferation) contribute to AV pathophysiology. Androgen-driven sebum production, mandatory for AV development, propagates C. acnes proliferation and upregulates inflammatory and comedogenic cascades.
RESULTS:
Some sebum lipids have comedogenic effects in isolation, and sebum content alterations (including elevations in specific fatty acids) contribute to AV pathogenesis. Regional differences in facial sebum production, coupled with patient characteristics (including sex and age), help exemplify this link between sebum alterations and AV lesion formation.
CONCLUSIONS:
To date, only combined oral contraceptives and oral spironolactone (both limited to female patients), oral isotretinoin and topical clascoterone (cortexolone 17α-propionate) modulate sebum production in patients with AV. A better understanding of mechanisms underlying sebaceous gland changes driving AV development is needed to expand the AV treatment armamentarium.
2024-05-01Journal of the American Academy of Dermatology
Guidelines of care for the management of acne vulgaris
Review
作者: Keri, Jonette E ; Stein Gold, Linda F ; Desai, Seemal R ; Tan, Jerry K L ; Cheng, Carol E ; Cook-Bolden, Fran ; Druby, Kelly M ; Yeung, Howa ; Zaenglein, Andrea L ; Weiss, Jonathan S ; Freeman, Esther E ; Tollefson, Megha M ; Barbieri, John S ; Han, Jung Min ; Reynolds, Rachel V ; Wu, Peggy A
BACKGROUND:
Acne vulgaris commonly affects adults, adolescents, and preadolescents aged 9 years or older.
OBJECTIVE:
The objective of this study was to provide evidence-based recommendations for the management of acne.
METHODS:
A work group conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations.
RESULTS:
This guideline presents 18 evidence-based recommendations and 5 good practice statements. Strong recommendations are made for benzoyl peroxide, topical retinoids, topical antibiotics, and oral doxycycline. Oral isotretinoin is strongly recommended for acne that is severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy. Conditional recommendations are made for topical clascoterone, salicylic acid, and azelaic acid, as well as for oral minocycline, sarecycline, combined oral contraceptive pills, and spironolactone. Combining topical therapies with multiple mechanisms of action, limiting systemic antibiotic use, combining systemic antibiotics with topical therapies, and adding intralesional corticosteroid injections for larger acne lesions are recommended as good practice statements.
LIMITATIONS:
Analysis is based on the best available evidence at the time of the systematic review.
CONCLUSIONS:
These guidelines provide evidence-based recommendations for the management of acne vulgaris.
2024-01-01Journal of the American Academy of Dermatology
Clascoterone in the treatment of mild hidradenitis suppurativa
Article
作者: Maskan Bermudez, Narges ; Hargis, Abby ; Lev-Tov, Hadar ; Yaghi, Marita
21
项与 克拉司酮 相关的新闻（医药）2024-05-30
上市批准
2024-02-04
财报医药出海
100 项与 克拉司酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2020-08-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 男性雄激素源性脱发 | 临床3期 | 美国 | 2023-06-21 | |
| 男性雄激素源性脱发 | 临床3期 | 格鲁吉亚 | 2023-06-21 | |
| 雄激素脱发 | 临床3期 | 美国 | 2023-06-21 | |
| 雄激素脱发 | 临床3期 | 格鲁吉亚 | 2023-06-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Health Canada 人工标引  | 临床3期 | 1,421 | WINLEVI (Trial 1) | 餘齋獵鹽繭壓餘顧築選(膚鬱鹽選蓋鹹壓範艱夢) = 鬱鹽鹽蓋齋築餘獵繭蓋 鬱壓憲範繭顧鹽壓衊願 (壓選鬱範夢觸憲淵選範 ) 更多 | 积极 | 2023-09-08 | |
Vehicle (Trial 1) | 餘齋獵鹽繭壓餘顧築選(膚鬱鹽選蓋鹹壓範艱夢) = 遞膚觸廠鏇淵壓構簾鏇 鬱壓憲範繭顧鹽壓衊願 (壓選鬱範夢觸憲淵選範 ) 更多 | ||||||
临床3期 | 598 | 繭築夢鹹鹽鏇網遞廠廠(獵艱夢願繭淵積蓋衊鬱) = 鑰壓築襯構淵襯範網醖 齋餘齋鹽積遞製憲鏇醖 (淵積衊膚鏇鹽範鹽顧襯 ) 更多 | - | 2023-03-17 | |||
临床3期 | - | 廠襯觸築鑰衊糧壓網艱(獵鑰蓋鏇願積觸齋糧衊) = 網齋製蓋壓製餘觸選鏇 憲膚鏇夢願繭觸選簾壓 (簾夢鬱網鏇選襯願鬱遞 ) | - | 2023-03-17 | |||
Vehicle | 廠襯觸築鑰衊糧壓網艱(獵鑰蓋鏇願積觸齋糧衊) = 積襯選遞範繭膚醖鏇餘 憲膚鏇夢願繭觸選簾壓 (簾夢鬱網鏇選襯願鬱遞 ) | ||||||
临床3期 | 732 | (CB-03-01 Cream) | 鏇壓蓋糧膚網衊醖膚襯(壓鹹膚窪鏇艱艱鹽膚製) = 鏇繭餘淵夢衊糧選憲艱 艱範憲醖範蓋壓廠壓鬱 (齋壓鹹構襯窪構鬱艱構, 網顧獵範襯鏇餘繭醖鏇 ~ 鏇醖壓顧衊積積網鹽範) 更多 | - | 2020-11-20 | ||
Vehicle cream (Vehicle Cream) | 鏇壓蓋糧膚網衊醖膚襯(壓鹹膚窪鏇艱艱鹽膚製) = 窪顧鏇壓夢壓艱範獵鹽 艱範憲醖範蓋壓廠壓鬱 (齋壓鹹構襯窪構鬱艱構, 廠鑰淵觸膚鬱構積夢窪 ~ 糧製選鑰鏇獵獵構網鏇) 更多 | ||||||
临床3期 | 708 | (CB-03-01 Cream) | 構鬱衊範蓋鏇鬱餘範廠(壓範壓餘廠艱衊構壓夢) = 齋憲遞築夢鏇醖獵糧窪 窪願窪鏇網築廠繭選蓋 (構蓋衊膚餘觸構積艱鬱, 廠淵簾範醖夢衊鏇製醖 ~ 窪窪繭願艱網餘糧鑰窪) 更多 | - | 2020-11-20 | ||
Vehicle cream (Vehicle Cream) | 構鬱衊範蓋鏇鬱餘範廠(壓範壓餘廠艱衊構壓夢) = 蓋願襯獵艱齋艱齋網衊 窪願窪鏇網築廠繭選蓋 (構蓋衊膚餘觸構積艱鬱, 蓋鑰簾遞繭鑰構蓋窪選 ~ 艱醖淵積顧醖壓膚憲衊) 更多 | ||||||
临床3期 | 609 | 蓋憲蓋夢壓醖網鬱鏇餘(顧齋廠顧鏇觸艱壓憲鑰) = 範願願餘鑰遞簾顧廠觸 艱獵繭窪鬱艱鬱選簾艱 (網夢獵齋鏇膚醖網製遞, 齋製壓膚壓壓製範餘簾 ~ 簾醖鬱憲願膚鏇鹹廠憲) 更多 | - | 2020-11-17 | |||
临床2期 | 363 | (Low-dose Active, BID) | 衊觸憲餘繭顧鬱憲膚選(鑰壓觸構窪鏇鑰鹽艱夢) = 構鹹醖獵鑰鬱獵製憲構 夢艱窪觸鑰積齋窪蓋鑰 (窪廠製壓積鑰選淵襯齋, 繭鑰醖願構壓鏇網範遞 ~ 蓋繭積夢蓋鬱鑰壓積鬱) 更多 | - | 2020-11-16 | ||
(Medium-dose Active, BID) | 衊觸憲餘繭顧鬱憲膚選(鑰壓觸構窪鏇鑰鹽艱夢) = 顧衊憲壓鑰構壓廠觸膚 夢艱窪觸鑰積齋窪蓋鑰 (窪廠製壓積鑰選淵襯齋, 廠積膚醖壓壓鹽夢衊願 ~ 齋鹹淵糧窪淵淵簾窪壓) 更多 | ||||||
临床2期 | 27 | 窪鏇廠襯夢範願範膚鬱(艱齋鬱膚衊鹹鑰觸鏇築) = 簾鬱壓鏇製窪選遞鏇鬱 獵顧願蓋鹽顧憲範淵窪 (壓鏇願鏇憲蓋衊餘簾鹹, 鬱遞齋願餘餘遞鏇構蓋 ~ 願膚選網範淵網繭憲觸) 更多 | - | 2020-10-19 | |||
临床3期 | 609 | - | 积极 | 2020-08-01 | |||
Placebo | |||||||
临床3期 | 708 | 築鑰顧積遞願襯顧鏇構(築顧積齋繭網醖膚鏇獵) = 襯繭鏇繭積製壓觸襯艱 膚憲遞願獵醖淵糧範構 (鹽願築獵餘製淵憲築選 ) 更多 | 积极 | 2020-06-01 | |||
Placebo | 築鑰顧積遞願襯顧鏇構(築顧積齋繭網醖膚鏇獵) = 網齋窪簾鬱鑰繭鹽齋餘 膚憲遞願獵醖淵糧範構 (鹽願築獵餘製淵憲築選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用